[HTML][HTML] Interleukin-6 interweaves the bone marrow microenvironment, bone loss, and multiple myeloma

D Harmer, C Falank, MR Reagan - Frontiers in endocrinology, 2019 - frontiersin.org
The immune system is strongly linked to the maintenance of healthy bone. Inflammatory
cytokines, specifically, are crucial to skeletal homeostasis and any dysregulation can result …

[HTML][HTML] Overcoming proteasome inhibitor resistance in the immunotherapy era

B Patiño-Escobar, A Talbot, AP Wiita - Trends in Pharmacological Sciences, 2023 - cell.com
Proteasome inhibitors (PIs) are a fascinating class of small molecules that disrupt protein
homeostasis and are highly efficacious in the blood cancer multiple myeloma. However, PIs …

[HTML][HTML] MicroRNAs as possible indicators of drug sensitivity in breast cancer cell lines

K Uhr, WJC Prager-van der Smissen, AAJ Heine… - PLoS …, 2019 - journals.plos.org
MicroRNAs (miRNAs) regulate gene expression post-transcriptionally. In this way they might
influence whether a cell is sensitive or resistant to a certain drug. So far, only a limited …

What sustains the multidrug resistance phenotype beyond ABC efflux transporters? Looking beyond the tip of the iceberg

T Alexa-Stratulat, M Pešić, AČ Gašparović… - Drug Resistance …, 2019 - Elsevier
Identification of multidrug (MDR) efflux transporters that belong to the ATP-Binding Cassette
(ABC) superfamily, represented an important breakthrough for understanding cancer …

[HTML][HTML] Sialyltransferase inhibition leads to inhibition of tumor cell interactions with E-selectin, VCAM1, and MADCAM1, and improves survival in a human multiple …

A Natoni, ML Farrell, S Harris, C Falank… - …, 2020 - ncbi.nlm.nih.gov
Aberrant glycosylation resulting from altered expression of sialyltransferases, such as ST3 β-
galactoside α2-3-sialyltransferase 6, plays an important role in disease progression in …

[HTML][HTML] Bone marrow stroma-induced transcriptome and regulome signatures of multiple myeloma

SA Dziadowicz, L Wang, H Akhter, D Aesoph… - Cancers, 2022 - mdpi.com
Simple Summary The bone marrow (BM) microenvironment provides a protective sanctuary
for multiple myeloma (MM) against therapeutic agents. MM cells interact with BM stromal …

DKK1 activates noncanonical NF-κB signaling via IL-6–induced CKAP4 receptor in multiple myeloma

X Li, J Wang, S Zhu, J Zheng, Y Xie, H Jiang… - Blood …, 2021 - ashpublications.org
Proteasome inhibitors, such as bortezomib (BTZ), represent the key elements in
chemotherapy regimens for multiple myeloma (MM), whereas acquired chemoresistance …

[PDF][PDF] Synergistic PIM kinase and proteasome inhibition as a therapeutic strategy for MYC-overexpressing triple-negative breast cancer

R Kunder, M Velyunskiy, SF Dunne, BK Cho… - Cell chemical …, 2022 - cell.com
Triple-negative breast cancer (TNBC) is the breast cancer subtype with the poorest clinical
outcome. The PIM family of kinases has emerged as a factor that is both overexpressed in …

[HTML][HTML] Proteasome inhibition is an effective treatment strategy for microsporidia infection in honey bees

EM Huntsman, RM Cho, HV Kogan… - Biomolecules, 2021 - mdpi.com
The microsporidia Nosema ceranae is an obligate intracellular parasite that causes honey
bee mortality and contributes to colony collapse. Fumagillin is presently the only …

[HTML][HTML] Therapeutics to harness the immune microenvironment in multiple myeloma

JJ Ignatz-Hoover, JJ Driscoll - Cancer Drug Resistance, 2022 - ncbi.nlm.nih.gov
Multiple myeloma (MM) remains an incurable, genetically heterogeneous disease
characterized by the uncontrolled proliferation of transformed plasma cells nurtured within a …